141 related articles for article (PubMed ID: 20063422)
1. Delayed administration of filgrastim (G-CSF) following autologous peripheral blood stem cell transplantation (APBSCT) in pediatric patients does not change time to neutrophil engraftment and reduces use of G-CSF.
Pai V; Fernandez SA; Laudick M; Rosselet R; Termuhlen A
Pediatr Blood Cancer; 2010 May; 54(5):728-33. PubMed ID: 20063422
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation.
Bence-Bruckler I; Bredeson C; Atkins H; McDiarmid S; Hamelin L; Hopkins H; Perry G; Genest P; Huebsch L
Bone Marrow Transplant; 1998 Nov; 22(10):965-9. PubMed ID: 9849693
[TBL] [Abstract][Full Text] [Related]
3. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
[TBL] [Abstract][Full Text] [Related]
4. Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF.
Milano-Bausset E; Gaudart J; Rome A; Coze C; Gentet JC; Padovani L; Lacarelle B; André N
Clin Ther; 2009; 31 Pt 2():2388-95. PubMed ID: 20110048
[TBL] [Abstract][Full Text] [Related]
5. A randomized, multicenter study of G-CSF starting on day +1 vs day +5 after autologous peripheral blood progenitor cell transplantation.
de Azevedo AM; Nucci M; Maiolino A; Vigorito AC; Simões BP; Aranha FJ; Tabak DG; Voltarelli J; de Souza CA
Bone Marrow Transplant; 2002 May; 29(9):745-51. PubMed ID: 12040471
[TBL] [Abstract][Full Text] [Related]
6. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor.
Watanabe H; Watanabe T; Suzuya H; Wakata Y; Kaneko M; Onishi T; Okamoto Y; Abe T; Kawano Y; Kagami S; Takaue Y
Bone Marrow Transplant; 2006 Apr; 37(7):661-8. PubMed ID: 16489358
[TBL] [Abstract][Full Text] [Related]
7. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
Weaver CH; Schulman KA; Buckner CD
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
[TBL] [Abstract][Full Text] [Related]
8. Individually determined dosing of filgrastim after autologous peripheral stem cell transplantation in patients with malignant lymphoma--results of a prospective multicentre controlled trial.
Faber E; Pytlík R; Slabý J; Zapletalová J; Kozák T; Raida L; Papajík T; Zikesová E; Maresová I; Hamouzová M; Indrák K; Trnený M
Eur J Haematol; 2006 Dec; 77(6):493-500. PubMed ID: 17042769
[TBL] [Abstract][Full Text] [Related]
9. Early vs delayed administration of G-CSF following autologous peripheral blood stem cell transplantation.
Colby C; McAfee SL; Finkelstein DM; Spitzer TR
Bone Marrow Transplant; 1998 May; 21(10):1005-10. PubMed ID: 9632273
[TBL] [Abstract][Full Text] [Related]
10. GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation.
Zumberg MS; Leather HL; Nejame C; Meyer C; Wingard JR
Cytotherapy; 2002; 4(6):531-8. PubMed ID: 12568989
[TBL] [Abstract][Full Text] [Related]
11. Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim.
Samaras P; Blickenstorfer M; Siciliano RD; Haile SR; Buset EM; Petrausch U; Mischo A; Honegger H; Schanz U; Stussi G; Stahel RA; Knuth A; Stenner-Liewen F; Renner C
Ann Hematol; 2011 Jan; 90(1):89-94. PubMed ID: 20706722
[TBL] [Abstract][Full Text] [Related]
12. Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma.
Fenk R; Hieronimus N; Steidl U; Bruns I; Graef T; Zohren F; Ruf L; Haas R; Kobbe G
Exp Hematol; 2006 Oct; 34(10):1296-302. PubMed ID: 16982322
[TBL] [Abstract][Full Text] [Related]
13. Optimal timing of G-CSF administration after CD34+ immunoselected peripheral blood progenitor cell transplantation.
Piccirillo N; Sica S; Laurenti L; Chiusolo P; La Barbera EO; Sorà F; Leone G
Bone Marrow Transplant; 1999 Jun; 23(12):1245-50. PubMed ID: 10414910
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation.
Gerds A; Fox-Geiman M; Dawravoo K; Rodriguez T; Toor A; Smith S; Kiley K; Fletcher-Gonzalez D; Hicks C; Stiff P
Biol Blood Marrow Transplant; 2010 May; 16(5):678-85. PubMed ID: 20045479
[TBL] [Abstract][Full Text] [Related]
15. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia.
Pui CH; Boyett JM; Hughes WT; Rivera GK; Hancock ML; Sandlund JT; Synold T; Relling MV; Ribeiro RC; Crist WM; Evans WE
N Engl J Med; 1997 Jun; 336(25):1781-7. PubMed ID: 9187068
[TBL] [Abstract][Full Text] [Related]
16. Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study.
Jagasia MH; Greer JP; Morgan DS; Mineishi S; Kassim AA; Ruffner KL; Chen H; Schuening FG
Bone Marrow Transplant; 2005 Jun; 35(12):1165-9. PubMed ID: 15880129
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of day 5 G-CSF (Lenograstim) administration after PBSC transplantation: results of a SFGM-TC randomised trial.
Valteau-Couanet D; Faucher C; Aupérin A; Michon J; Milpied N; Boiron JM; Bourhis JH; Gisselbrecht C; Vernant JP; Pinna A; Bendahmane B; Delabarre F; Benhamou E
Bone Marrow Transplant; 2005 Sep; 36(6):547-52. PubMed ID: 16007101
[TBL] [Abstract][Full Text] [Related]
18. Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: a randomized study.
Faucher C; Le Corroller AG; Chabannon C; Novakovitch G; Manonni P; Moatti JP; Nouyrigat P; Maraninchi D; Blaise D
Bone Marrow Transplant; 1996 Apr; 17(4):533-6. PubMed ID: 8722350
[TBL] [Abstract][Full Text] [Related]
19. Comparison of lenograstim and filgrastim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy.
Kim IH; Park SK; Suh OK; Oh JM
Curr Med Res Opin; 2003; 19(8):753-9. PubMed ID: 14687447
[TBL] [Abstract][Full Text] [Related]
20. Delayed introduction of G-CSF after chemotherapy does not affect peripheral blood stem cell yield and engraftment kinetics in children with high-risk malignancies: retrospective study of 45 cases.
Dolgopolov I; Andreeva L; Yankelevich M; Mscheidze D; Siegel S; Mentkevich G
Am J Hematol; 2003 Aug; 73(4):225-9. PubMed ID: 12879423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
